Vaccination with fusion cells plus edodekin alfa may be of benefit in patients with recurrent malignant glioma

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1474, 2005-01, pp. : 7-7

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Survival of Patients with Recurrent Malignant Glioma Treated with Temozolomide: A Retrospective Observational Study

By Trippoli S. Pelagotti F. Messori A. Vacca F. Vaiani M. Maltoni S.

Drugs in R&D, Vol. 4, Iss. 5, 2003-01 ,pp. : 285-291

Adis International

Access to resources Recommend Favorite

B-cell lymphoma vaccination may benefit certain patients with NHL

Inpharma, Vol. 1, Iss. 1475, 2005-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

On the significance of telomerase activity in human malignant glioma cells

By Vietor M. Winter S. Groscurth P. Naumann U. Weller M.

European Journal of Pharmacology, Vol. 407, Iss. 1, 2000-10 ,pp. : 27-37

Elsevier

Access to resources Recommend Favorite

A20 is overexpressed in glioma cells and may serve as a potential therapeutic target

By Guo Qingdong Dong Hui Liu Xiaonan Wang Chunmei Liu Nannan Zhang Jianning Li Bing Cao Weidong Ding Tianbing Yang Zengyue Zhang Xiang

Expert Opinion on Therapeutic Targets, Vol. 13, Iss. 7, 2009-07 ,pp. : 733-741

Informa Healthcare

Access to resources Recommend Favorite

Interleukin (IL)-13 PE38QQR shows promise in the treatment of recurrent malignant glioma

Inpharma, Vol. 1, Iss. 1415, 2003-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite